Summary
28 patients with diabetic retinopathy randomly received oral treatment with a bovine factor VIII peptide fraction (Vueffe®) 0.5mg twice daily or calcium-dobesilate (Doxium®) 500mg twice daily for 4 months. Changes in the activity of plasma factor VIII fractions [von Willebrand factor (vWf); factor VIII-related antigen (FVIII:Ag); and factor VIII procoagulant activity (FVIII:C)] were determined during treatment, and compared at baseline with a control group of 10 diabetic patients without retinopathy. Bovine factor VIII peptide fraction reduced the high levels of vWf and FVII:Ag to values found in control patients without retinopathy, while no effect on FVIII:C was detected. Bovine factor VIII peptide fraction produced a statistically significantly greater reduction in vWf and FVIII:Ag than calcium-dobesilate: the percentage reduction of vWf was 33 vs 11 (p < 0.01), that of FVIII:Ag was 25 vs 7 (p < 0.01). In addition, the retinopathy improvement rate was 47% for bovine factor VIII peptide fraction and 8% for calcium-dobesilate (p = 0.037). It is concluded that bovine factor VIII peptide fraction improves diabetic retinopathy by lessening endothelial damage to retinal microvessels by reducing plasma vWf and FVIII:Ag activity.
Similar content being viewed by others
References
Ammannati P, Siravo D, Azzarelli L, Chimenti M, Salvetti O, et al. Decrease of diffusion of glycosylated albumin in retinal microcirculation by peptide fraction from bovine factor VIII. Arzneimittel-Forschung 39: 661–664, 1989
Baldacci M, Catalani R, Fascetti E, Gervasi GR. Polypeptide fraction from bovine factor VIII does not influence platelet aggregation and blood coagulation. Pharmacological Research Communications 20: 7–12, 1988
Colmann RW, Hirsh J, Marder VJ, Salzmann EW. Retinal microangiopathy, haemostasis and thrombosis: basic principles and clinical practice. Lippincott, Philadelphia, 1987
Denson KWE. Factor VIII procoagulant activity: method of determination. In Biggs (Ed.) Human coagulation, haemostasis and thrombosis, p. 278, Blackwell Scientific Publishers, Oxford, 1972
Foster PA, Fulcher CA, Houghten RA, Mahoney SG, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, two amino acid residues Threonine-Serine of the factor VIII heavy chain. Journal of Clinical Investigation 82: 123–128, 1988
Gervasi GB, Bartoli C, Carpita G, Baldacci M. Decrease of bleeding time by a peptidic fraction from bovine factor VIII in laboratory animals. Arzneimittel-Forschung 38: 1268–1270, 1988
Jandie JH. Disorders of blood coagulation. In Jandle (Ed.) Blood: pathophysiology. Blackwell Scientific Publications, Oxford, 1991
Martindale. James E.F. Reynolds (Ed.) The Extra Pharmacopea 29th ed., London, 1989
Morse PH. Diabetic oculopathy. In De Groot (Ed.) Endocrinology, Vol. 2, Saunders, Philadelphia, 1989
Pandolfi M, Lars-Olaf A, Lars H. Increased von Willebrand antihaemophilic factor A in diabetic retinopathy. Acta Ophthalmologica 52: 823–828, 1974
Raines G, Aumann H, Sykes S, Streat A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thrombosis Research 60: 201–212, 1990
Sakariassen KS, Fressinaud E, Girma JP, Baumgartner HR, Meyer D. Mediation of platelet adhesion to fibrillar collagen in flowing blood by proteolytic fragment of human von Willebrand factor. Blood 67: 1515–1518, 1986
Tuddenham EGD, Lazarchick J, Hoyer LW. Synthesis and release of factor VIII by cultured human endothelial cells. British Journal of Haematology 47: 617–626, 1981
Witte S. Coagulation factors and permeability process. Clinical Hemorheology 2: 561–577, 1982
Witte S. Surface phenomena of coagulation factors in vivo, observed by fluorescence intravital microscopy. Annals of the New York Academy of Sciences 416: 426–438, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cardillo-Piccolino, F., Ghiglione, D., Santini, G. et al. Treatment of Nonproliferative Diabetic Retinopathy with a Peptide Fraction from Bovine Factor VIII. Drug Invest 4, 1–6 (1992). https://doi.org/10.1007/BF03258371
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258371